HROW
Harrow Health Inc
30.50$
-0.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +9.0% | -5.2% | +3.8% | +14.6% | +10.6% | -6.4% | -5.3% | +5.2% | +10.0% | +5.0% | -0.6% | |
| – | +26.1% | -9.8% | +11.1% | +5.5% | +29.0% | -10.6% | -8.6% | +14.7% | +19.2% | +6.9% | +1.3% | |
| – | +12.9% | -7.5% | +3.5% | +2.3% | -34.9% | +41.2% | -20.6% | +40.3% | -1.8% | +29.8% | -11.4% | |
| – | +12.0% | -8.2% | -6.6% | +2.3% | -34.9% | +41.2% | -16.4% | +33.1% | -1.8% | +29.8% | -11.4% | |
| – | +95.2% | -20.0% | +78.9% | +3.3% | +116.1% | -33.7% | +2.0% | -1.3% | +42.5% | -8.7% | +17.1% | |
| – | +21.8% | -0.5% | -12.8% | +7.8% | +5.4% | +0.1% | +7.8% | +11.1% | +5.4% | +22.0% | +2.5% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -1.7% | -0.3% | -1.6% | +21.9% | -2.3% | -2.3% | -2.3% | -2.4% | +0.8% | +4.0% | -2.9% | |
| – | +14.8% | -2.7% | +5.6% | +18.3% | +8.8% | -3.6% | -4.0% | +7.0% | +9.8% | +12.6% | +2.8% | |
| – | +159.3% | -15.4% | +28.3% | +77.4% | -3.9% | +104.7% | +33.1% | -73.7% | +47.3% | -5.0% | +11.7% | |
| – | +2.7% | -1.4% | -3.5% | -33.9% | -2.0% | +21,816.3% | +69.3% | -99.5% | +3.3% | +3.2% | +3.2% | |
| – | +255.6% | -41.3% | +60.6% | +25.3% | +53.3% | -4.3% | -36.9% | -18.9% | +86.1% | -26.1% | +30.4% | |
| – | +0.5% | +0.5% | +0.5% | +0.6% | +18.0% | -48.8% | -65.8% | +531.1% | +0.1% | +20.1% | +0.1% | |
| – | -7.1% | -13.9% | -3.4% | -0.9% | +20.1% | -19.0% | -12.0% | -5.3% | +11.5% | -45.3% | -47.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +3.2% | +0.3% | +0.4% | +0.2% | +0.3% | +0.1% | +8.5% | +0.1% | -5.4% | +1.3% | +0.3% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.